Abstract
Schizophrenia is a chronic and severe neuropsychiatric condition manifested by cognitive, emotional, affective, perceptual, and behavioral abnormalities. Despite decades of research, the biological substrates driving the signs and symptoms of the disorder remain elusive, thus hampering progress in the development of treatments aimed at disease etiologies. The recent emergence of human induced pluripotent stem cell (hiPSC)-based models has provided the field with a highly innovative approach to generate, study, and manipulate living neural tissue derived from patients, making possible the exploration of fundamental roles of genes and early-life stressors in disease-relevant cell types. Here, we begin with a brief overview of the clinical, epidemiological, and genetic aspects of the condition, with a focus on schizophrenia as a neurodevelopmental disorder. We then highlight relevant technical advancements in hiPSC models and assess novel findings attained using hiPSC-based approaches and their implications for disease biology and treatment innovation. We close with a critical appraisal of the developments necessary for both further expanding knowledge of schizophrenia and the translation of new insights into therapeutic innovations.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Carpenter Jr., W. T., Strauss, J. S., & Bartko, J. J. (1974). An approach to the diagnosis and understanding of schizophrenia. Introduction. Schizophrenia Bulletin (11), 35–36. https://doi.org/10.1093/schbul/1.11.35
Crow, T. J. (1985). The two-syndrome concept: origins and current status. Schizophrenia Bulletin, 11(3), 471–486.
Sartorius, N., Shapiro, R., Kimura, M., & Barrett, K. (1972). WHO international pilot study of schizophrenia. Psychological Medicine, 2(4), 422–425.
Strauss, J. S., Carpenter Jr., W. T., & Bartko, J. J. (1974). The diagnosis and understanding of schizophrenia. Summary and conclusions. Schizophrenia Bulletin (11), 70–80.
Kay, S. R., Opler, L. A., & Lindenmayer, J. P. (1988). Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Research, 23(1), 99–110.
Lindenmayer, J. P., Bernstein-Hyman, R., & Grochowski, S. (1994). A new five factor model of schizophrenia. Psychiatric Quarterly, 65(4), 299–322.
Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R., & Dickinson, D. (2012). Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophrenia Research, 137(1–3), 246–250. https://doi.org/10.1016/j.schres.2012.01.031
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: Author.
Staehelin, J. E., & Kielholz, P. (1953). Largactil, a new vegetative damping agent in mental disorders. Schweizerische Medizinische Wochenschrift, 83(25), 581–586.
Carlsson, A., & Lindqvist, M. (1963). Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica, 20, 140–144.
Creese, I., Burt, D. R., & Snyder, S. H. (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192(4238), 481–483.
Seeman, P., & Lee, T. (1975). Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science, 188(4194), 1217–1219.
Borison, R. L., Pathiraja, A. P., Diamond, B. I., & Meibach, R. C. (1992). Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin, 28(2), 213–218.
Jones, P. B., Barnes, T. R., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., et al. (2006). Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry, 63(10), 1079–1087. https://doi.org/10.1001/archpsyc.63.10.1079
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine, 353(12), 1209–1223. https://doi.org/10.1056/NEJMoa051688
Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45(9), 789–796.
Fusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., et al. (2015). Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophrenia Bulletin, 41(4), 892–899. https://doi.org/10.1093/schbul/sbu170
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, 382(9896), 951–962. https://doi.org/10.1016/S0140-6736(13)60733-3
Naber, D., & Lambert, M. (2009). The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs, 23(8), 649–659. https://doi.org/10.2165/00023210-200923080-00002
Downing, A. M., Kinon, B. J., Millen, B. A., Zhang, L., Liu, L., Morozova, M. A., et al. (2014). A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry, 14, 351. https://doi.org/10.1186/s12888-014-0351-3
Jablensky, A., Sartorius, N., Ernberg, G., Anker, M., Korten, A., Cooper, J. E., et al. (1992). Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine. Monograph Supplement, 20, 1–97.
Hjorthoj, C., Sturup, A. E., McGrath, J. J., & Nordentoft, M. (2017). Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry, 4(4), 295–301. https://doi.org/10.1016/S2215-0366(17)30078-0
Palmer, B. A., Pankratz, V. S., & Bostwick, J. M. (2005). The lifetime risk of suicide in schizophrenia: a reexamination. Archives of General Psychiatry, 62(3), 247–253. https://doi.org/10.1001/archpsyc.62.3.247
Caldwell, C. B., & Gottesman, I. I. (1990). Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophrenia Bulletin, 16(4), 571–589.
Phillips, M. R., Yang, G., Li, S., & Li, Y. (2004). Suicide and the unique prevalence pattern of schizophrenia in mainland China: a retrospective observational study. Lancet, 364(9439), 1062–1068. https://doi.org/10.1016/S0140-6736(04)17061-X
Brown, S. (1997). Excess mortality of schizophrenia. A meta-analysis. The British Journal of Psychiatry, 171, 502–508.
Weinmann, S., Read, J., & Aderhold, V. (2009). Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophrenia Research, 113(1), 1–11. https://doi.org/10.1016/j.schres.2009.05.018
Nielsen, P. R., Laursen, T. M., & Agerbo, E. (2016). Comorbidity of schizophrenia and infection: a population-based cohort study. Social Psychiatry and Psychiatric Epidemiology, 51(12), 1581–1589. https://doi.org/10.1007/s00127-016-1297-1
Goff, D. C., Cather, C., Evins, A. E., Henderson, D. C., Freudenreich, O., Copeland, P. M., et al. (2005). Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. Journal of Clinical Psychiatry, 66(2), 183–194; quiz 147, 273-184.
Winklbaur, B., Ebner, N., Sachs, G., Thau, K., & Fischer, G. (2006). Substance abuse in patients with schizophrenia. Dialogues in Clinical Neuroscience, 8(1), 37–43.
Brekke, J. S., Prindle, C., Bae, S. W., & Long, J. D. (2001). Risks for individuals with schizophrenia who are living in the community. Psychiatric Services, 52(10), 1358–1366. https://doi.org/10.1176/appi.ps.52.10.1358
Rapoport, J. L., Addington, A. M., Frangou, S., & Psych, M. R. (2005). The neurodevelopmental model of schizophrenia: update 2005. Molecular Psychiatry, 10(5), 434–449. https://doi.org/10.1038/sj.mp.4001642
Rapoport, J. L., Giedd, J. N., & Gogtay, N. (2012). Neurodevelopmental model of schizophrenia: update 2012. Molecular Psychiatry, 17(12), 1228–1238. https://doi.org/10.1038/mp.2012.23
Stiles, J., & Jernigan, T. L. (2010). The basics of brain development. Neuropsychology Review, 20(4), 327–348. https://doi.org/10.1007/s11065-010-9148-4
Muraki, K., & Tanigaki, K. (2015). Neuronal migration abnormalities and its possible implications for schizophrenia. Frontiers in Neuroscience, 9, 74. https://doi.org/10.3389/fnins.2015.00074
Schoenfeld, T. J., & Cameron, H. A. (2015). Adult neurogenesis and mental illness. Neuropsychopharmacology, 40(1), 113–128. https://doi.org/10.1038/npp.2014.230
Schmidt, M. J., & Mirnics, K. (2015). Neurodevelopment, GABA system dysfunction, and schizophrenia. Neuropsychopharmacology, 40(1), 190–206. https://doi.org/10.1038/npp.2014.95
Bartzokis, G. (2002). Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuropsychopharmacology, 27(4), 672–683. https://doi.org/10.1016/S0893-133X(02)00364-0
Forsyth, J. K., & Lewis, D. A. (2017). Mapping the consequences of impaired synaptic plasticity in schizophrenia through development: an integrative model for diverse clinical features. Trends in Cognitive Sciences, 21(10), 760–778. https://doi.org/10.1016/j.tics.2017.06.006
Hirayasu, Y., Shenton, M. E., Salisbury, D. F., Dickey, C. C., Fischer, I. A., Mazzoni, P., et al. (1998). Lower left temporal lobe MRI volumes in patients with first-episode schizophrenia compared with psychotic patients with first-episode affective disorder and normal subjects. The American Journal of Psychiatry, 155(10), 1384–1391. https://doi.org/10.1176/ajp.155.10.1384
Wilke, M., Kaufmann, C., Grabner, A., Putz, B., Wetter, T. C., & Auer, D. P. (2001). Gray matter-changes and correlates of disease severity in schizophrenia: a statistical parametric mapping study. NeuroImage, 13(5), 814–824. https://doi.org/10.1006/nimg.2001.0751
Salgado-Pineda, P., Baeza, I., Perez-Gomez, M., Vendrell, P., Junque, C., Bargallo, N., et al. (2003). Sustained attention impairment correlates to gray matter decreases in first episode neuroleptic-naive schizophrenic patients. NeuroImage, 19(2 Pt 1), 365–375.
Berge, D., Carmona, S., Rovira, M., Bulbena, A., Salgado, P., & Vilarroya, O. (2011). Gray matter volume deficits and correlation with insight and negative symptoms in first-psychotic-episode subjects. Acta Psychiatrica Scandinavica, 123(6), 431–439. https://doi.org/10.1111/j.1600-0447.2010.01635.x
Hirayasu, Y., Tanaka, S., Shenton, M. E., Salisbury, D. F., DeSantis, M. A., Levitt, J. J., et al. (2001). Prefrontal gray matter volume reduction in first episode schizophrenia. Cerebral Cortex, 11(4), 374–381.
Paillere-Martinot, M., Caclin, A., Artiges, E., Poline, J. B., Joliot, M., Mallet, L., et al. (2001). Cerebral gray and white matter reductions and clinical correlates in patients with early onset schizophrenia. Schizophrenia Research, 50(1–2), 19–26.
Crespo-Facorro, B., Roiz-Santianez, R., Perez-Iglesias, R., Rodriguez-Sanchez, J. M., Mata, I., Tordesillas-Gutierrez, D., et al. (2011). Global and regional cortical thinning in first-episode psychosis patients: relationships with clinical and cognitive features. Psychological Medicine, 41(7), 1449–1460. https://doi.org/10.1017/S003329171000200X
Whitford, T. J., Grieve, S. M., Farrow, T. F., Gomes, L., Brennan, J., Harris, A. W., et al. (2006). Progressive grey matter atrophy over the first 2–3 years of illness in first-episode schizophrenia: a tensor-based morphometry study. NeuroImage, 32(2), 511–519. https://doi.org/10.1016/j.neuroimage.2006.03.041
Hirayasu, Y., Shenton, M. E., Salisbury, D. F., Kwon, J. S., Wible, C. G., Fischer, I. A., et al. (1999). Subgenual cingulate cortex volume in first-episode psychosis. The American Journal of Psychiatry, 156(7), 1091–1093. https://doi.org/10.1176/ajp.156.7.1091
Kasai, K., Shenton, M. E., Salisbury, D. F., Onitsuka, T., Toner, S. K., Yurgelun-Todd, D., et al. (2003). Differences and similarities in insular and temporal pole MRI gray matter volume abnormalities in first-episode schizophrenia and affective psychosis. Archives of General Psychiatry, 60(11), 1069–1077. https://doi.org/10.1001/archpsyc.60.11.1069
Rothlisberger, M., Riecher-Rossler, A., Aston, J., Fusar-Poli, P., Radu, E. W., & Borgwardt, S. (2012). Cingulate volume abnormalities in emerging psychosis. Current Pharmaceutical Design, 18(4), 495–504.
Liu, J., Pearlson, G., Windemuth, A., Ruano, G., Perrone-Bizzozero, N. I., & Calhoun, V. (2009). Combining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA. Human Brain Mapping, 30(1), 241–255. https://doi.org/10.1002/hbm.20508
Carpenter, D. M., Tang, C. Y., Friedman, J. I., Hof, P. R., Stewart, D. G., Buchsbaum, M. S., et al. (2008). Temporal characteristics of tract-specific anisotropy abnormalities in schizophrenia. Neuroreport, 19(14), 1369–1372. https://doi.org/10.1097/WNR.0b013e32830abc35
Karlsgodt, K. H., van Erp, T. G., Poldrack, R. A., Bearden, C. E., Nuechterlein, K. H., & Cannon, T. D. (2008). Diffusion tensor imaging of the superior longitudinal fasciculus and working memory in recent-onset schizophrenia. Biological Psychiatry, 63(5), 512–518. https://doi.org/10.1016/j.biopsych.2007.06.017
Perez-Iglesias, R., Tordesillas-Gutierrez, D., Barker, G. J., McGuire, P. K., Roiz-Santianez, R., Mata, I., et al. (2010). White matter defects in first episode psychosis patients: a voxelwise analysis of diffusion tensor imaging. NeuroImage, 49(1), 199–204. https://doi.org/10.1016/j.neuroimage.2009.07.016
Ruef, A., Curtis, L., Moy, G., Bessero, S., Badan Ba, M., Lazeyras, F., et al. (2012). Magnetic resonance imaging correlates of first-episode psychosis in young adult male patients: combined analysis of grey and white matter. Journal of Psychiatry & Neuroscience, 37(5), 305–312. https://doi.org/10.1503/jpn.110057
White, T., Anjum, A., & Schulz, S. C. (2006). The schizophrenia prodrome. The American Journal of Psychiatry, 163(3), 376–380. https://doi.org/10.1176/appi.ajp.163.3.376
Yung, A. R., & McGorry, P. D. (1996a). The initial prodrome in psychosis: descriptive and qualitative aspects. The Australian and New Zealand Journal of Psychiatry, 30(5), 587–599. https://doi.org/10.3109/00048679609062654
Beiser, M., Erickson, D., Fleming, J. A., & Iacono, W. G. (1993). Establishing the onset of psychotic illness. The American Journal of Psychiatry, 150(9), 1349–1354. https://doi.org/10.1176/ajp.150.9.1349
Lencz, T., Cornblatt, B., & Bilder, R. M. (2001). Neurodevelopmental models of schizophrenia: pathophysiologic synthesis and directions for intervention research. Psychopharmacology Bulletin, 35(1), 95–125.
Tsuang, M. T., Faraone, S. V., Bingham, S., Young, K., Prabhudesai, S., Haverstock, S. L., et al. (2000). Department of Veterans Affairs Cooperative Studies Program genetic linkage study of schizophrenia: ascertainment methods and sample description. American Journal of Medical Genetics, 96(3), 342–347.
Yung, A. R., & McGorry, P. D. (1996b). The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophrenia Bulletin, 22(2), 353–370.
Cornblatt, B., Lencz, T., & Obuchowski, M. (2002). The schizophrenia prodrome: treatment and high-risk perspectives. Schizophrenia Research, 54(1–2), 177–186.
Cornblatt, B., Obuchowski, M., Roberts, S., Pollack, S., & Erlenmeyer-Kimling, L. (1999). Cognitive and behavioral precursors of schizophrenia. Development and Psychopathology, 11(3), 487–508.
Lappin, J. M., Dazzan, P., Morgan, K., Morgan, C., Chitnis, X., Suckling, J., et al. (2007). Duration of prodromal phase and severity of volumetric abnormalities in first-episode psychosis. The British Journal of Psychiatry. Supplement, 51, s123–s127. https://doi.org/10.1192/bjp.191.51.s123
Fusar-Poli, P., Tantardini, M., De Simone, S., Ramella-Cravaro, V., Oliver, D., Kingdon, J., et al. (2017). Deconstructing vulnerability for psychosis: meta-analysis of environmental risk factors for psychosis in subjects at ultra high-risk. European Psychiatry, 40, 65–75. https://doi.org/10.1016/j.eurpsy.2016.09.003
Clarke, M. C., Tanskanen, A., Huttunen, M., Leon, D. A., Murray, R. M., Jones, P. B., et al. (2011). Increased risk of schizophrenia from additive interaction between infant motor developmental delay and obstetric complications: evidence from a population-based longitudinal study. The American Journal of Psychiatry, 168(12), 1295–1302. https://doi.org/10.1176/appi.ajp.2011.11010011
Jones, P., Rodgers, B., Murray, R., & Marmot, M. (1994). Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet, 344(8934), 1398–1402.
Kremen, W. S., Buka, S. L., Seidman, L. J., Goldstein, J. M., Koren, D., & Tsuang, M. T. (1998). IQ decline during childhood and adult psychotic symptoms in a community sample: a 19-year longitudinal study. The American Journal of Psychiatry, 155(5), 672–677. https://doi.org/10.1176/ajp.155.5.672
Wood, S. J., Pantelis, C., Proffitt, T., Phillips, L. J., Stuart, G. W., Buchanan, J. A., et al. (2003). Spatial working memory ability is a marker of risk-for-psychosis. Psychological Medicine, 33(7), 1239–1247.
Brewer, W. J., Francey, S. M., Wood, S. J., Jackson, H. J., Pantelis, C., Phillips, L. J., et al. (2005). Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. The American Journal of Psychiatry, 162(1), 71–78. https://doi.org/10.1176/appi.ajp.162.1.71
Dickson, H., Laurens, K. R., Cullen, A. E., & Hodgins, S. (2012). Meta-analyses of cognitive and motor function in youth aged 16 years and younger who subsequently develop schizophrenia. Psychological Medicine, 42(4), 743–755. https://doi.org/10.1017/S0033291711001693
Erlenmeyer-Kimling, L., Rock, D., Roberts, S. A., Janal, M., Kestenbaum, C., Cornblatt, B., et al. (2000). Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project. The American Journal of Psychiatry, 157(9), 1416–1422. https://doi.org/10.1176/appi.ajp.157.9.1416
Done, D. J., Crow, T. J., Johnstone, E. C., & Sacker, A. (1994). Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. BMJ, 309(6956), 699–703.
Davidson, M., Reichenberg, A., Rabinowitz, J., Weiser, M., Kaplan, Z., & Mark, M. (1999). Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. The American Journal of Psychiatry, 156(9), 1328–1335. https://doi.org/10.1176/ajp.156.9.1328
Klosterkotter, J., Hellmich, M., Steinmeyer, E. M., & Schultze-Lutter, F. (2001). Diagnosing schizophrenia in the initial prodromal phase. Archives of General Psychiatry, 58(2), 158–164.
Pantelis, C., Velakoulis, D., McGorry, P. D., Wood, S. J., Suckling, J., Phillips, L. J., et al. (2003). Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet, 361(9354), 281–288. https://doi.org/10.1016/S0140-6736(03)12323-9
Borgwardt, S. J., McGuire, P. K., Aston, J., Berger, G., Dazzan, P., Gschwandtner, U., et al. (2007). Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. The British Journal of Psychiatry. Supplement, 51, s69–s75. https://doi.org/10.1192/bjp.191.51.s69
Fornito, A., Yung, A. R., Wood, S. J., Phillips, L. J., Nelson, B., Cotton, S., et al. (2008). Anatomic abnormalities of the anterior cingulate cortex before psychosis onset: an MRI study of ultra-high-risk individuals. Biological Psychiatry, 64(9), 758–765. https://doi.org/10.1016/j.biopsych.2008.05.032
Takahashi, T., Wood, S. J., Soulsby, B., Kawasaki, Y., McGorry, P. D., Suzuki, M., et al. (2009a). An MRI study of the superior temporal subregions in first-episode patients with various psychotic disorders. Schizophrenia Research, 113(2–3), 158–166. https://doi.org/10.1016/j.schres.2009.06.016
Takahashi, T., Wood, S. J., Yung, A. R., Phillips, L. J., Soulsby, B., McGorry, P. D., et al. (2009b). Insular cortex gray matter changes in individuals at ultra-high-risk of developing psychosis. Schizophrenia Research, 111(1–3), 94–102. https://doi.org/10.1016/j.schres.2009.03.024
Mechelli, A., Riecher-Rossler, A., Meisenzahl, E. M., Tognin, S., Wood, S. J., Borgwardt, S. J., et al. (2011). Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. Archives of General Psychiatry, 68(5), 489–495. https://doi.org/10.1001/archgenpsychiatry.2011.42
Fusar-Poli, P., Broome, M. R., Woolley, J. B., Johns, L. C., Tabraham, P., Bramon, E., et al. (2011). Altered brain function directly related to structural abnormalities in people at ultra high risk of psychosis: longitudinal VBM-fMRI study. Journal of Psychiatric Research, 45(2), 190–198. https://doi.org/10.1016/j.jpsychires.2010.05.012
Jung, W. H., Kim, J. S., Jang, J. H., Choi, J. S., Jung, M. H., Park, J. Y., et al. (2011). Cortical thickness reduction in individuals at ultra-high-risk for psychosis. Schizophrenia Bulletin, 37(4), 839–849. https://doi.org/10.1093/schbul/sbp151
Gilmore, J. H., Kang, C., Evans, D. D., Wolfe, H. M., Smith, J. K., Lieberman, J. A., et al. (2010a). Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia. The American Journal of Psychiatry, 167(9), 1083–1091. https://doi.org/10.1176/appi.ajp.2010.09101492
Gilmore, J. H., Schmitt, J. E., Knickmeyer, R. C., Smith, J. K., Lin, W., Styner, M., et al. (2010b). Genetic and environmental contributions to neonatal brain structure: A twin study. Human Brain Mapping, 31(8), 1174–1182. https://doi.org/10.1002/hbm.20926
Walterfang, M., McGuire, P. K., Yung, A. R., Phillips, L. J., Velakoulis, D., Wood, S. J., et al. (2008). White matter volume changes in people who develop psychosis. The British Journal of Psychiatry, 193(3), 210–215. https://doi.org/10.1192/bjp.bp.107.043463
Bloemen, O. J., de Koning, M. B., Schmitz, N., Nieman, D. H., Becker, H. E., de Haan, L., et al. (2010). White-matter markers for psychosis in a prospective ultra-high-risk cohort. Psychological Medicine, 40(8), 1297–1304. https://doi.org/10.1017/S0033291709991711
Brown, A. S. (2006). Prenatal infection as a risk factor for schizophrenia. Schizophrenia Bulletin, 32(2), 200–202. https://doi.org/10.1093/schbul/sbj052
Brown, A. S. (2012). Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism. Developmental Neurobiology, 72(10), 1272–1276. https://doi.org/10.1002/dneu.22024
Cannon, M., Jones, P. B., & Murray, R. M. (2002). Obstetric complications and schizophrenia: historical and meta-analytic review. The American Journal of Psychiatry, 159(7), 1080–1092. https://doi.org/10.1176/appi.ajp.159.7.1080
Picker, J. D., & Coyle, J. T. (2005). Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase risk for schizophrenia? Harvard Review of Psychiatry, 13(4), 197–205. https://doi.org/10.1080/10673220500243372
Roseboom, T. J., Painter, R. C., van Abeelen, A. F., Veenendaal, M. V., & de Rooij, S. R. (2011). Hungry in the womb: what are the consequences? Lessons from the Dutch famine. Maturitas, 70(2), 141–145. https://doi.org/10.1016/j.maturitas.2011.06.017
Knud Larsen, J., Bendsen, B. B., Foldager, L., & Munk-Jorgensen, P. (2010). Prematurity and low birth weight as risk factors for the development of affective disorder, especially depression and schizophrenia: a register study. Acta Neuropsychiatrica, 22(6), 284–291. https://doi.org/10.1111/j.1601-5215.2010.00498.x
Rifkin, L., Lewis, S., Jones, P., Toone, B., & Murray, R. (1994). Low birth weight and schizophrenia. The British Journal of Psychiatry, 165(3), 357–362.
Wahlbeck, K., Forsen, T., Osmond, C., Barker, D. J., & Eriksson, J. G. (2001). Association of schizophrenia with low maternal body mass index, small size at birth, and thinness during childhood. Archives of General Psychiatry, 58(1), 48–52.
Torniainen, M., Wegelius, A., Tuulio-Henriksson, A., Lonnqvist, J., & Suvisaari, J. (2013). Both low birthweight and high birthweight are associated with cognitive impairment in persons with schizophrenia and their first-degree relatives. Psychological Medicine, 43(11), 2361–2367. https://doi.org/10.1017/S0033291713000032
Moilanen, K., Jokelainen, J., Jones, P. B., Hartikainen, A. L., Jarvelin, M. R., & Isohanni, M. (2010). Deviant intrauterine growth and risk of schizophrenia: a 34-year follow-up of the Northern Finland 1966 Birth Cohort. Schizophrenia Research, 124(1–3), 223–230. https://doi.org/10.1016/j.schres.2010.09.006
Davies, G., Welham, J., Chant, D., Torrey, E. F., & McGrath, J. (2003). A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophrenia Bulletin, 29(3), 587–593.
Frissen, A., Lieverse, R., Drukker, M., van Winkel, R., Delespaul, P., & Investigators, G. (2015). Childhood trauma and childhood urbanicity in relation to psychotic disorder. Social Psychiatry and Psychiatric Epidemiology, 50(10), 1481–1488. https://doi.org/10.1007/s00127-015-1049-7
Lataster, J., Myin-Germeys, I., Lieb, R., Wittchen, H. U., & van Os, J. (2012). Adversity and psychosis: a 10-year prospective study investigating synergism between early and recent adversity in psychosis. Acta Psychiatrica Scandinavica, 125(5), 388–399. https://doi.org/10.1111/j.1600-0447.2011.01805.x
Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42(5), 1262–1269. https://doi.org/10.1093/schbul/sbw003
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., et al. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet, 370(9584), 319–328. https://doi.org/10.1016/S0140-6736(07)61162-3
Heinz, A., Deserno, L., & Reininghaus, U. (2013). Urbanicity, social adversity and psychosis. World Psychiatry, 12(3), 187–197. https://doi.org/10.1002/wps.20056
Lichtenstein, P., Yip, B. H., Bjork, C., Pawitan, Y., Cannon, T. D., Sullivan, P. F., et al. (2009). Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet, 373(9659), 234–239. https://doi.org/10.1016/S0140-6736(09)60072-6
Lichtenstein, P., Bjork, C., Hultman, C. M., Scolnick, E., Sklar, P., & Sullivan, P. F. (2006). Recurrence risks for schizophrenia in a Swedish national cohort. Psychological Medicine, 36(10), 1417–1425. https://doi.org/10.1017/S0033291706008385
Cardno, A. G., & Gottesman, I. I. (2000). Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. American Journal of Medical Genetics, 97(1), 12–17.
Hilker, R., Helenius, D., Fagerlund, B., Skytthe, A., Christensen, K., Werge, T. M., et al. (2018). Heritability of schizophrenia and schizophrenia spectrum based on the Nationwide Danish Twin Register. Biological Psychiatry, 83(6), 492–498. https://doi.org/10.1016/j.biopsych.2017.08.017
Sullivan, P. F., Agrawal, A., Bulik, C. M., Andreassen, O. A., Borglum, A. D., Breen, G., et al. (2018). Psychiatric genomics: an update and an agenda. The American Journal of Psychiatry, 175(1), 15–27. https://doi.org/10.1176/appi.ajp.2017.17030283
Power, R. A., Kyaga, S., Uher, R., MacCabe, J. H., Langstrom, N., Landen, M., et al. (2013). Fecundity of patients with schizophrenia, autism, bipolar disorder, depression, anorexia nervosa, or substance abuse vs their unaffected siblings. JAMA Psychiatry, 70(1), 22–30. https://doi.org/10.1001/jamapsychiatry.2013.268
Gershon, E. S., Alliey-Rodriguez, N., & Liu, C. (2011). After GWAS: searching for genetic risk for schizophrenia and bipolar disorder. The American Journal of Psychiatry, 168(3), 253–256. https://doi.org/10.1176/appi.ajp.2010.10091340
Malaspina, D., Brown, A., Goetz, D., Alia-Klein, N., Harkavy-Friedman, J., Harlap, S., et al. (2002). Schizophrenia risk and paternal age: a potential role for de novo mutations in schizophrenia vulnerability genes. CNS Spectrums, 7(1), 26–29.
Kong, A., Frigge, M. L., Masson, G., Besenbacher, S., Sulem, P., Magnusson, G., et al. (2012). Rate of de novo mutations and the importance of father's age to disease risk. Nature, 488(7412), 471–475. https://doi.org/10.1038/nature11396
Gulsuner, S., Walsh, T., Watts, A. C., Lee, M. K., Thornton, A. M., Casadei, S., et al. (2013). Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell, 154(3), 518–529. https://doi.org/10.1016/j.cell.2013.06.049
Xu, B., Ionita-Laza, I., Roos, J. L., Boone, B., Woodrick, S., Sun, Y., et al. (2012). De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nature Genetics, 44(12), 1365–1369. https://doi.org/10.1038/ng.2446
Fromer, M., Pocklington, A. J., Kavanagh, D. H., Williams, H. J., Dwyer, S., Gormley, P., et al. (2014). De novo mutations in schizophrenia implicate synaptic networks. Nature, 506(7487), 179–184. https://doi.org/10.1038/nature12929
Awadalla, P., Gauthier, J., Myers, R. A., Casals, F., Hamdan, F. F., Griffing, A. R., et al. (2010). Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. American Journal of Human Genetics, 87(3), 316–324. https://doi.org/10.1016/j.ajhg.2010.07.019
Girard, S. L., Gauthier, J., Noreau, A., Xiong, L., Zhou, S., Jouan, L., et al. (2011). Increased exonic de novo mutation rate in individuals with schizophrenia. Nature Genetics, 43(9), 860–863. https://doi.org/10.1038/ng.886
Purcell, S. M., Moran, J. L., Fromer, M., Ruderfer, D., Solovieff, N., Roussos, P., et al. (2014). A polygenic burden of rare disruptive mutations in schizophrenia. Nature, 506(7487), 185–190. https://doi.org/10.1038/nature12975
Genovese, G., Fromer, M., Stahl, E. A., Ruderfer, D. M., Chambert, K., Landen, M., et al. (2016). Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. Nature Neuroscience, 19(11), 1433–1441. https://doi.org/10.1038/nn.4402
Genovese G., Fromer M., Stahl E. A., Ruderfer D. M., Chambert K., Landén M., et al. (2016) Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. Nature Neuroscience 19(11):1433–1441
Szatkiewicz, J. P., O'Dushlaine, C., Chen, G., Chambert, K., Moran, J. L., Neale, B. M., et al. (2014). Copy number variation in schizophrenia in Sweden. Molecular Psychiatry, 19(7), 762–773. https://doi.org/10.1038/mp.2014.40
Rees, E., Kirov, G., O'Donovan, M. C., & Owen, M. J. (2012). De novo mutation in schizophrenia. Schizophrenia Bulletin, 38(3), 377–381. https://doi.org/10.1093/schbul/sbs047
Marshall, C. R., Howrigan, D. P., Merico, D., Thiruvahindrapuram, B., Wu, W., Greer, D. S., et al. (2017). Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics, 49(1), 27–35. https://doi.org/10.1038/ng.3725
Schneider, M., Debbane, M., Bassett, A. S., Chow, E. W., Fung, W. L., van den Bree, M., et al. (2014). Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 deletion syndrome. The American Journal of Psychiatry, 171(6), 627–639. https://doi.org/10.1176/appi.ajp.2013.13070864
Van, L., Boot, E., & Bassett, A. S. (2017). Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia. Current Opinion in Psychiatry, 30(3), 191–196. https://doi.org/10.1097/YCO.0000000000000324
Bergen, S. E., Ploner, A., Howrigan, D., CNV Analysis Group and the Schizophrenia Working Group of the Psychiatric Genomics Consortium, O’Donovan, M. C., Smoller, J. W., et al. (2018). Joint contributions of rare copy number variants and common SNPs to risk for schizophrenia. Am J Psychiatry, 176, 29. https://doi.org/10.1176/appi.ajp.2018.17040467
Tansey, K. E., Rees, E., Linden, D. E., Ripke, S., Chambert, K. D., Moran, J. L., et al. (2016). Common alleles contribute to schizophrenia in CNV carriers. Molecular Psychiatry, 21(8), 1153. https://doi.org/10.1038/mp.2015.170
Gottesman, I. I., & Shields, J. (1967). A polygenic theory of schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 58(1), 199–205.
Shi, J., Levinson, D. F., Duan, J., Sanders, A. R., Zheng, Y., Pe'er, I., et al. (2009). Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature, 460(7256), 753–757. https://doi.org/10.1038/nature08192
International Schizophrenia Consortium, Purcell, S. M., Wray, N. R., Stone, J. L., Visscher, P. M., O'Donovan, M. C., et al. (2009). Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature, 460(7256), 748–752. https://doi.org/10.1038/nature08185
O'Donovan, M. C., Craddock, N., Norton, N., Williams, H., Peirce, T., Moskvina, V., et al. (2008). Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nature Genetics, 40(9), 1053–1055. https://doi.org/10.1038/ng.201
Stefansson, H., Ophoff, R. A., Steinberg, S., Andreassen, O. A., Cichon, S., Rujescu, D., et al. (2009). Common variants conferring risk of schizophrenia. Nature, 460(7256), 744–747. https://doi.org/10.1038/nature08186
Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, Ripke, S., Sanders, A. R., Kendler, K. S., Levinson, D. F., Sklar, P., et al. (2011). Genome-wide association study identifies five new schizophrenia loci. Nature Genetics, 43(10), 969–976. https://doi.org/10.1038/ng.940
Ripke, S., O'Dushlaine, C., Chambert, K., Moran, J. L., Kahler, A. K., Akterin, S., et al. (2013). Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nature Genetics, 45(10), 1150–1159. https://doi.org/10.1038/ng.2742
Schmitt, A., Malchow, B., Hasan, A., & Falkai, P. (2014). The impact of environmental factors in severe psychiatric disorders. Frontiers in Neuroscience, 8, 19. https://doi.org/10.3389/fnins.2014.00019
Pardinas, A. F., Holmans, P., Pocklington, A. J., Escott-Price, V., Ripke, S., Carrera, N., et al. (2018). Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nature Genetics, 50(3), 381–389. https://doi.org/10.1038/s41588-018-0059-2
Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 511(7510), 421–427. https://doi.org/10.1038/nature13595
Li, Z., Chen, J., Yu, H., He, L., Xu, Y., Zhang, D., et al. (2017). Genome-wide association analysis identifies 30 new susceptibility loci for schizophrenia. Nature Genetics, 49(11), 1576–1583. https://doi.org/10.1038/ng.3973
Shi, Y., Li, Z., Xu, Q., Wang, T., Li, T., Shen, J., et al. (2011). Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nature Genetics, 43(12), 1224–1227. https://doi.org/10.1038/ng.980
GTEx Consortium, Laboratory, Data Analysis &Coordinating Center (LDACC)—Analysis Working Group, Statistical Methods groups—Analysis Working Group, Enhancing GTEx (eGTEx) groups, NIH Common Fund, NIH/NCI, et al. (2017). Genetic effects on gene expression across human tissues. Nature, 550(7675), 204–213. https://doi.org/10.1038/nature24277
Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., et al. (2012). Systematic localization of common disease-associated variation in regulatory DNA. Science, 337(6099), 1190–1195. https://doi.org/10.1126/science.1222794
Albert, F. W., & Kruglyak, L. (2015). The role of regulatory variation in complex traits and disease. Nature Reviews Genetics, 16(4), 197–212. https://doi.org/10.1038/nrg3891
Ng, B., White, C. C., Klein, H. U., Sieberts, S. K., McCabe, C., Patrick, E., et al. (2017). An xQTL map integrates the genetic architecture of the human brain’s transcriptome and epigenome. Nature Neuroscience, 20(10), 1418–1426. https://doi.org/10.1038/nn.4632
Gandal, M. J., Zhang, P., Hadjimichael, E., Walker, R. L., Chen, C., Liu, S., et al. (2018). Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science, 362(6420). https://doi.org/10.1126/science.aat8127
Rajarajan, P., Gil, S. E., Brennand, K. J., & Akbarian, S. (2016). Spatial genome organization and cognition. Nature Reviews Neuroscience, 17(11), 681–691. https://doi.org/10.1038/nrn.2016.124
Richards, A. L., Jones, L., Moskvina, V., Kirov, G., Gejman, P. V., Levinson, D. F., et al. (2012). Schizophrenia susceptibility alleles are enriched for alleles that affect gene expression in adult human brain. Molecular Psychiatry, 17(2), 193–201. https://doi.org/10.1038/mp.2011.11
Fromer, M., Roussos, P., Sieberts, S. K., Johnson, J. S., Kavanagh, D. H., Perumal, T. M., et al. (2016). Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nature Neuroscience, 19(11), 1442–1453. https://doi.org/10.1038/nn.4399
de la Torre-Ubieta, L., Stein, J. L., Won, H., Opland, C. K., Liang, D., Lu, D., et al. (2018). The dynamic landscape of open chromatin during human cortical neurogenesis. Cell2, 172(1–2), 289–304, e218. https://doi.org/10.1016/j.cell.2017.12.014
Jaffe, A. E., Straub, R. E., Shin, J. H., Tao, R., Gao, Y., Collado-Torres, L., et al. (2018). Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis. Nature Neuroscience, 21(8), 1117–1125. https://doi.org/10.1038/s41593-018-0197-y
Zhang, Y. E., Landback, P., Vibranovski, M. D., & Long, M. (2011). Accelerated recruitment of new brain development genes into the human genome. PLoS Biology, 9(10), e1001179. https://doi.org/10.1371/journal.pbio.1001179
Akbarian, S., Bunney Jr., W. E., Potkin, S. G., Wigal, S. B., Hagman, J. O., Sandman, C. A., et al. (1993). Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Archives of General Psychiatry, 50(3), 169–177.
Jakob, H., & Beckmann, H. (1986). Prenatal developmental disturbances in the limbic allocortex in schizophrenics. Journal of Neural Transmission, 65(3–4), 303–326.
Fung, S. J., Webster, M. J., Sivagnanasundaram, S., Duncan, C., Elashoff, M., & Weickert, C. S. (2010). Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. The American Journal of Psychiatry, 167(12), 1479–1488. https://doi.org/10.1176/appi.ajp.2010.09060784
Hyde, T. M., Lipska, B. K., Ali, T., Mathew, S. V., Law, A. J., Metitiri, O. E., et al. (2011). Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia. The Journal of Neuroscience, 31(30), 11088–11095. https://doi.org/10.1523/JNEUROSCI.1234-11.2011
Horváth S., Janka Z., Mirnics K., (2011) Analyzing Schizophrenia by DNA Microarrays. Biological Psychiatry 69(2):157–162
Torkamani, A., Dean, B., Schork, N. J., & Thomas, E. A. (2010). Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Research, 20(4), 403–412. https://doi.org/10.1101/gr.101956.109
Mistry, M., Gillis, J., & Pavlidis, P. (2013a). Genome-wide expression profiling of schizophrenia using a large combined cohort. Molecular Psychiatry, 18(2), 215–225. https://doi.org/10.1038/mp.2011.172
Mistry, M., Gillis, J., & Pavlidis, P. (2013b). Meta-analysis of gene coexpression networks in the post-mortem prefrontal cortex of patients with schizophrenia and unaffected controls. BMC Neuroscience, 14, 105. https://doi.org/10.1186/1471-2202-14-105
Finucane, H. K., Reshef, Y. A., Anttila, V., Slowikowski, K., Gusev, A., Byrnes, A., et al. (2018). Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. Nature Genetics, 50(4), 621–629. https://doi.org/10.1038/s41588-018-0081-4
Gusev, A., Mancuso, N., Won, H., Kousi, M., Finucane, H. K., Reshef, Y., et al. (2018). Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. Nature Genetics, 50(4), 538–548. https://doi.org/10.1038/s41588-018-0092-1
Skene, N. G., Bryois, J., Bakken, T. E., Breen, G., Crowley, J. J., Gaspar, H. A., et al. (2018). Genetic identification of brain cell types underlying schizophrenia. Nature Genetics, 50(6), 825–833. https://doi.org/10.1038/s41588-018-0129-5
Roussos, P., Katsel, P., Davis, K. L., Siever, L. J., & Haroutunian, V. (2012). A system-level transcriptomic analysis of schizophrenia using postmortem brain tissue samples. Archives of General Psychiatry, 69(12), 1205–1213. https://doi.org/10.1001/archgenpsychiatry.2012.704
Radulescu, E., Jaffe, A. E., Straub, R. E., Chen, Q., Shin, J. H., Hyde, T. M., et al. (2018). Identification and prioritization of gene sets associated with schizophrenia risk by co-expression network analysis in human brain. Molecular Psychiatry. https://doi.org/10.1038/s41380-018-0304-1
Gusev, A., Ko, A., Shi, H., Bhatia, G., Chung, W., Penninx, B. W., et al. (2016). Integrative approaches for large-scale transcriptome-wide association studies. Nature Genetics, 48(3), 245–252. https://doi.org/10.1038/ng.3506
Huckins L. M., Dobbyn A., Ruderfer D. M., Hoffman G., Wang W., Pardiñas A. F., et al. (2019) Gene expression imputation across multiple brain regions provides insights into schizophrenia risk. Nature Genetics 51(4):659–674
The Network, O'Dushlaine, C., Rossin, L., Lee, P. H., Duncan, L., Parikshak, N. N., et al. (2015). Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nature Neuroscience, 18, 199. https://doi.org/10.1038/nn.3922. https://www.nature.com/articles/nn.3922#supplementary-information
Trynka, G., Sandor, C., Han, B., Xu, H., Stranger, B. E., Liu, X. S., et al. (2013). Chromatin marks identify critical cell types for fine mapping complex trait variants. Nature Genetics, 45(2), 124–130. https://doi.org/10.1038/ng.2504
Roussos, P., Mitchell, A. C., Voloudakis, G., Fullard, J. F., Pothula, V. M., Tsang, J., et al. (2014). A role for noncoding variation in schizophrenia. Cell Reports, 9(4), 1417–1429. https://doi.org/10.1016/j.celrep.2014.10.015
Psych, E. C., Akbarian, S., Liu, C., Knowles, J. A., Vaccarino, F. M., Farnham, P. J., et al. (2015). The PsychENCODE project. Nature Neuroscience, 18(12), 1707–1712. https://doi.org/10.1038/nn.4156
Girdhar, K., Hoffman, G. E., Jiang, Y., Brown, L., Kundakovic, M., Hauberg, M. E., et al. (2018). Cell-specific histone modification maps in the human frontal lobe link schizophrenia risk to the neuronal epigenome. Nature Neuroscience, 21(8), 1126–1136. https://doi.org/10.1038/s41593-018-0187-0
Jaffe, A. E., Gao, Y., Deep-Soboslay, A., Tao, R., Hyde, T. M., Weinberger, D. R., et al. (2016). Mapping DNA methylation across development, genotype and schizophrenia in the human frontal cortex. Nature Neuroscience, 19(1), 40–47. https://doi.org/10.1038/nn.4181
Schulz, H., Ruppert, A. K., Herms, S., Wolf, C., Mirza-Schreiber, N., Stegle, O., et al. (2017). Genome-wide mapping of genetic determinants influencing DNA methylation and gene expression in human hippocampus. Nature Communications, 8(1), 1511. https://doi.org/10.1038/s41467-017-01818-4
Dobbyn, A., Huckins, L. M., Boocock, J., Sloofman, L. G., Glicksberg, B. S., Giambartolomei, C., et al. (2018). Landscape of conditional eQTL in dorsolateral prefrontal cortex and co-localization with schizophrenia GWAS. American Journal of Human Genetics, 102(6), 1169–1184. https://doi.org/10.1016/j.ajhg.2018.04.011
Rajarajan, P., Borrman, T., Liao, W., Schrode, N., Flaherty, E., Casino, C., et al. (2018a). Neuron-specific signatures in the chromosomal connectome associated with schizophrenia risk. Science, 362(6420), eaat4311. https://doi.org/10.1126/science.aat4311
Bharadwaj, R., Jiang, Y., Mao, W., Jakovcevski, M., Dincer, A., Krueger, W., et al. (2013). Conserved chromosome 2q31 conformations are associated with transcriptional regulation of GAD1 GABA synthesis enzyme and altered in prefrontal cortex of subjects with schizophrenia. The Journal of Neuroscience, 33(29), 11839–11851. https://doi.org/10.1523/JNEUROSCI.1252-13.2013
Bharadwaj, R., Peter, C. J., Jiang, Y., Roussos, P., Vogel-Ciernia, A., Shen, E. Y., et al. (2014). Conserved higher-order chromatin regulates NMDA receptor gene expression and cognition. Neuron, 84(5), 997–1008. https://doi.org/10.1016/j.neuron.2014.10.032
Bryois, J., Garrett, M. E., Song, L., Safi, A., Giusti-Rodriguez, P., Johnson, G. D., et al. (2018). Evaluation of chromatin accessibility in prefrontal cortex of individuals with schizophrenia. Nature Communications, 9(1), 3121. https://doi.org/10.1038/s41467-018-05379-y
Fullard, J. F., Giambartolomei, C., Hauberg, M. E., Xu, K., Voloudakis, G., Shao, Z., et al. (2017). Open chromatin profiling of human postmortem brain infers functional roles for non-coding schizophrenia loci. Human Molecular Genetics, 26(10), 1942–1951. https://doi.org/10.1093/hmg/ddx103
Fullard, J. F., Hauberg, M. E., Bendl, J., Egervari, G., Cirnaru, M. D., Reach, S. M., et al. (2018). An atlas of chromatin accessibility in the adult human brain. Genome Research, 28(8), 1243–1252. https://doi.org/10.1101/gr.232488.117
Won, H., de la Torre-Ubieta, L., Stein, J. L., Parikshak, N. N., Huang, J., Opland, C. K., et al. (2016). Chromosome conformation elucidates regulatory relationships in developing human brain. Nature, 538(7626), 523–527. https://doi.org/10.1038/nature19847
Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663–676. https://doi.org/10.1016/j.cell.2006.07.024
Narsinh, K. H., Plews, J., & Wu, J. C. (2011). Comparison of human induced pluripotent and embryonic stem cells: fraternal or identical twins? Molecular Therapy, 19(4), 635–638. https://doi.org/10.1038/mt.2011.41
Hoffman, G. E., Schrode, N., Flaherty, E., & Brennand, K. J. (2018). New considerations for hiPSC-based models of neuropsychiatric disorders. Molecular Psychiatry, 24, 49. https://doi.org/10.1038/s41380-018-0029-1
Laurent, L. C., Ulitsky, I., Slavin, I., Tran, H., Schork, A., Morey, R., et al. (2011). Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell, 8(1), 106–118. https://doi.org/10.1016/j.stem.2010.12.003
Lister, R., Pelizzola, M., Kida, Y. S., Hawkins, R. D., Nery, J. R., Hon, G., et al. (2011). Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature, 471(7336), 68–73. https://doi.org/10.1038/nature09798
Julia, T. C. W., Carvalho, C. M. B., Yuan, B., Gu, S., Altheimer, A. N., McCarthy, S., et al. (2017). Divergent levels of marker chromosomes in an hiPSC-based model of psychosis. Stem Cell Reports, 8(3), 519–528. https://doi.org/10.1016/j.stemcr.2017.01.010
Grochowski, C. M., Gu, S., Yuan, B., Tcw, J., Brennand, K. J., Sebat, J., et al. (2018). Marker chromosome genomic structure and temporal origin implicate a chromoanasynthesis event in a family with pleiotropic psychiatric phenotypes. Human Mutation, 39(7), 939–946. https://doi.org/10.1002/humu.23537
Kyttala, A., Moraghebi, R., Valensisi, C., Kettunen, J., Andrus, C., Pasumarthy, K. K., et al. (2016). Genetic variability overrides the impact of parental cell type and determines iPSC Differentiation Potential. Stem Cell Reports, 6(2), 200–212. https://doi.org/10.1016/j.stemcr.2015.12.009
Hoffman, G. E., Hartley, B. J., Flaherty, E., Ladran, I., Gochman, P., Ruderfer, D. M., et al. (2017). Transcriptional signatures of schizophrenia in hiPSC-derived NPCs and neurons are concordant with post-mortem adult brains. Nature Communications, 8(1), 2225. https://doi.org/10.1038/s41467-017-02330-5
Nehme, R., Zuccaro, E., Ghosh, S. D., Li, C., Sherwood, J. L., Pietilainen, O., et al. (2018). Combining NGN2 Programming with developmental patterning generates human excitatory neurons with NMDAR-mediated synaptic transmission. Cell Reports, 23(8), 2509–2523. https://doi.org/10.1016/j.celrep.2018.04.066
Mertens, J., Marchetto, M. C., Bardy, C., & Gage, F. H. (2016). Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience. Nature Reviews Neuroscience, 17(7), 424–437. https://doi.org/10.1038/nrn.2016.46
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nature Biotechnology, 27(3), 275–280. https://doi.org/10.1038/nbt.1529
Marchetto, M. C., Carromeu, C., Acab, A., Yu, D., Yeo, G. W., Mu, Y., et al. (2010). A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell, 143(4), 527–539. https://doi.org/10.1016/j.cell.2010.10.016
Maroof, A. M., Keros, S., Tyson, J. A., Ying, S. W., Ganat, Y. M., Merkle, F. T., et al. (2013). Directed differentiation and functional maturation of cortical interneurons from human embryonic stem cells. Cell Stem Cell, 12(5), 559–572. https://doi.org/10.1016/j.stem.2013.04.008
Kriks, S., Shim, J. W., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., et al. (2011). Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature, 480(7378), 547–551. https://doi.org/10.1038/nature10648
Lu J., Zhong X., Liu H., Hao L., Tzu-Ling Huang C., Sherafat M. A., et al. (2016) Generation of serotonin neurons from human pluripotent stem cells. Nature Biotechnology 34(1):89–94
Yu, D. X., Di Giorgio, F. P., Yao, J., Marchetto, M. C., Brennand, K., Wright, R., et al. (2014). Modeling hippocampal neurogenesis using human pluripotent stem cells. Stem Cell Reports, 2(3), 295–310. https://doi.org/10.1016/j.stemcr.2014.01.009
Sarkar, A., Mei, A., Paquola, A. C. M., Stern, S., Bardy, C., Klug, J. R., et al. (2018). Efficient generation of CA3 neurons from human pluripotent stem cells enables modeling of hippocampal connectivity in vitro. Cell Stem Cell, 22(5), 684–697. e689. https://doi.org/10.1016/j.stem.2018.04.009
Qi, Y., Zhang, X. J., Renier, N., Wu, Z., Atkin, T., Sun, Z., et al. (2017). Combined small-molecule inhibition accelerates the derivation of functional cortical neurons from human pluripotent stem cells. Nature Biotechnology, 35(2), 154–163. https://doi.org/10.1038/nbt.3777
Schwartzentruber, J., Foskolou, S., Kilpinen, H., Rodrigues, J., Alasoo, K., Knights, A. J., et al. (2018). Molecular and functional variation in iPSC-derived sensory neurons. Nature Genetics, 50(1), 54–61. https://doi.org/10.1038/s41588-017-0005-8
Kuijlaars, J., Oyelami, T., Diels, A., Rohrbacher, J., Versweyveld, S., Meneghello, G., et al. (2016). Sustained synchronized neuronal network activity in a human astrocyte co-culture system. Scientific Reports, 6, 36529. https://doi.org/10.1038/srep36529
Gunhanlar, N., Shpak, G., van der Kroeg, M., Gouty-Colomer, L. A., Munshi, S. T., Lendemeijer, B., et al. (2018). A simplified protocol for differentiation of electrophysiologically mature neuronal networks from human induced pluripotent stem cells. Molecular Psychiatry, 23(5), 1336–1344. https://doi.org/10.1038/mp.2017.56
Vierbuchen, T., Ostermeier, A., Pang, Z. P., Kokubu, Y., Sudhof, T. C., & Wernig, M. (2010). Direct conversion of fibroblasts to functional neurons by defined factors. Nature, 463(7284), 1035–1041. https://doi.org/10.1038/nature08797
Pang, Z. P., Yang, N., Vierbuchen, T., Ostermeier, A., Fuentes, D. R., Yang, T. Q., et al. (2011). Induction of human neuronal cells by defined transcription factors. Nature, 476(7359), 220–223. https://doi.org/10.1038/nature10202
Zhang, Y., Pak, C., Han, Y., Ahlenius, H., Zhang, Z., Chanda, S., et al. (2013). Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron, 78(5), 785–798. https://doi.org/10.1016/j.neuron.2013.05.029
Ho, S. M., Hartley, B. J., Tcw, J., Beaumont, M., Stafford, K., Slesinger, P. A., et al. (2016). Rapid Ngn2-induction of excitatory neurons from hiPSC-derived neural progenitor cells. Methods, 101, 113–124. https://doi.org/10.1016/j.ymeth.2015.11.019
Colasante, G., Lignani, G., Rubio, A., Medrihan, L., Yekhlef, L., Sessa, A., et al. (2015). Rapid conversion of fibroblasts into functional forebrain GABAergic interneurons by direct genetic reprogramming. Cell Stem Cell, 17(6), 719–734. https://doi.org/10.1016/j.stem.2015.09.002
Sun, A. X., Yuan, Q., Tan, S., Xiao, Y., Wang, D., Khoo, A. T., et al. (2016). Direct induction and functional maturation of forebrain GABAergic neurons from human pluripotent stem cells. Cell Reports, 16(7), 1942–1953. https://doi.org/10.1016/j.celrep.2016.07.035
Yang, N., Chanda, S., Marro, S., Ng, Y. H., Janas, J. A., Haag, D., et al. (2017). Generation of pure GABAergic neurons by transcription factor programming. Nature Methods, 14(6), 621–628. https://doi.org/10.1038/nmeth.4291
Caiazzo, M., Dell'Anno, M. T., Dvoretskova, E., Lazarevic, D., Taverna, S., Leo, D., et al. (2011). Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature, 476(7359), 224–227. https://doi.org/10.1038/nature10284
Theka, I., Caiazzo, M., Dvoretskova, E., Leo, D., Ungaro, F., Curreli, S., et al. (2013). Rapid generation of functional dopaminergic neurons from human induced pluripotent stem cells through a single-step procedure using cell lineage transcription factors. Stem Cells Translational Medicine, 2(6), 473–479. https://doi.org/10.5966/sctm.2012-0133
Lu, J., Zhong, X., Liu, H., Hao, L., Huang, C. T., Sherafat, M. A., et al. (2016). Generation of serotonin neurons from human pluripotent stem cells. Nature Biotechnology, 34(1), 89–94. https://doi.org/10.1038/nbt.3435
Vadodaria, K. C., Mertens, J., Paquola, A., Bardy, C., Li, X., Jappelli, R., et al. (2016). Generation of functional human serotonergic neurons from fibroblasts. Molecular Psychiatry, 21(1), 49–61. https://doi.org/10.1038/mp.2015.161
Brennand, K. J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., et al. (2011). Modelling schizophrenia using human induced pluripotent stem cells. Nature, 473(7346), 221–225. https://doi.org/10.1038/nature09915
Hook, V., Brennand, K. J., Kim, Y., Toneff, T., Funkelstein, L., Lee, K. C., et al. (2014). Human iPSC neurons display activity-dependent neurotransmitter secretion: aberrant catecholamine levels in schizophrenia neurons. Stem Cell Reports, 3(4), 531–538. https://doi.org/10.1016/j.stemcr.2014.08.001
Robicsek, O., Karry, R., Petit, I., Salman-Kesner, N., Muller, F. J., Klein, E., et al. (2013). Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients. Molecular Psychiatry, 18(10), 1067–1076. https://doi.org/10.1038/mp.2013.67
Xu, J., Hartley, B. J., Kurup, P., Phillips, A., Topol, A., Xu, M., et al. (2018). Inhibition of STEP61 ameliorates deficits in mouse and hiPSC-based schizophrenia models. Molecular Psychiatry, 23(2), 271–281. https://doi.org/10.1038/mp.2016.163
Carty, N. C., Xu, J., Kurup, P., Brouillette, J., Goebel-Goody, S. M., Austin, D. R., et al. (2012). The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. Translational Psychiatry, 2, e137. https://doi.org/10.1038/tp.2012.63
Brennand, K., Savas, J. N., Kim, Y., Tran, N., Simone, A., Hashimoto-Torii, K., et al. (2015). Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia. Molecular Psychiatry, 20(3), 361–368. https://doi.org/10.1038/mp.2014.22
Topol, A., English, J. A., Flaherty, E., Rajarajan, P., Hartley, B. J., Gupta, S., et al. (2015a). Increased abundance of translation machinery in stem cell-derived neural progenitor cells from four schizophrenia patients. Translational Psychiatry, 5, e662. https://doi.org/10.1038/tp.2015.118
Topol, A., Zhu, S., Tran, N., Simone, A., Fang, G., & Brennand, K. J. (2015b). Altered WNT signaling in human induced pluripotent stem cell neural progenitor cells derived from four schizophrenia patients. Biological Psychiatry, 78(6), e29–e34. https://doi.org/10.1016/j.biopsych.2014.12.028
Casas, B. S., Vitoria, G., do Costa, M. N., Madeiro da Costa, R., Trindade, P., Maciel, R., et al. (2018). hiPSC-derived neural stem cells from patients with schizophrenia induce an impaired angiogenesis. Translational Psychiatry, 8(1), 48. https://doi.org/10.1038/s41398-018-0095-9
Hino, M., Kunii, Y., Matsumoto, J., Wada, A., Nagaoka, A., Niwa, S., et al. (2016). Decreased VEGFR2 expression and increased phosphorylated Akt1 in the prefrontal cortex of individuals with schizophrenia. Journal of Psychiatric Research, 82, 100–108. https://doi.org/10.1016/j.jpsychires.2016.07.018
Lee, B. H., Hong, J. P., Hwang, J. A., Ham, B. J., Na, K. S., Kim, W. J., et al. (2015). Alterations in plasma vascular endothelial growth factor levels in patients with schizophrenia before and after treatment. Psychiatry Research, 228(1), 95–99. https://doi.org/10.1016/j.psychres.2015.04.020
Lopes, R., Soares, R., Coelho, R., & Figueiredo-Braga, M. (2015). Angiogenesis in the pathophysiology of schizophrenia - a comprehensive review and a conceptual hypothesis. Life Sciences, 128, 79–93. https://doi.org/10.1016/j.lfs.2015.02.010
Gonzalez, D. M., Gregory, J., & Brennand, K. J. (2017). The importance of non-neuronal cell types in hiPSC-based disease modeling and drug screening. Frontiers in Cell and Development Biology, 5, 117. https://doi.org/10.3389/fcell.2017.00117
Ben-Shachar, D. (2002). Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. Journal of Neurochemistry, 83(6), 1241–1251.
Prabakaran, S., Swatton, J. E., Ryan, M. M., Huffaker, S. J., Huang, J. T., Griffin, J. L., et al. (2004). Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Molecular Psychiatry, 9(7), 684–697, 643. https://doi.org/10.1038/sj.mp.4001511
Uguz, A. C., Demirci, K., & Espino, J. (2016). The importance of melatonin and mitochondria interaction in mood disorders and schizophrenia: a current assessment. Current Medicinal Chemistry, 23(20), 2146–2158.
Paulsen Bda, S., de Moraes Maciel, R., Galina, A., Souza da Silveira, M., dos Santos Souza, C., Drummond, H., et al. (2012). Altered oxygen metabolism associated to neurogenesis of induced pluripotent stem cells derived from a schizophrenic patient. Cell Transplantation, 21(7), 1547–1559. https://doi.org/10.3727/096368911X600957
Robicsek, O., Ene, H. M., Karry, R., Ytzhaki, O., Asor, E., McPhie, D., et al. (2018). Isolated mitochondria transfer improves neuronal differentiation of schizophrenia-derived induced pluripotent stem cells and rescues deficits in a rat model of the disorder. Schizophrenia Bulletin, 44(2), 432–442. https://doi.org/10.1093/schbul/sbx077
Caputo, V., Ciolfi, A., Macri, S., & Pizzuti, A. (2015). The emerging role of MicroRNA in schizophrenia. CNS & Neurological Disorders Drug Targets, 14(2), 208–221.
Shi, S., Leites, C., He, D., Schwartz, D., Moy, W., Shi, J., et al. (2014). MicroRNA-9 and microRNA-326 regulate human dopamine D2 receptor expression, and the microRNA-mediated expression regulation is altered by a genetic variant. The Journal of Biological Chemistry, 289(19), 13434–13444. https://doi.org/10.1074/jbc.M113.535203
Han, J., Kim, H. J., Schafer, S. T., Paquola, A., Clemenson, G. D., Toda, T., et al. (2016). Functional implications of miR-19 in the migration of newborn neurons in the adult brain. Neuron, 91(1), 79–89. https://doi.org/10.1016/j.neuron.2016.05.034
Topol, A., Zhu, S., Hartley, B. J., English, J., Hauberg, M. E., Tran, N., et al. (2016). Dysregulation of miRNA-9 in a subset of schizophrenia patient-derived neural progenitor cells. Cell Reports, 15(5), 1024–1036. https://doi.org/10.1016/j.celrep.2016.03.090
Hauberg, M. E., Roussos, P., Grove, J., Borglum, A. D., Mattheisen, M., & Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2016). Analyzing the role of MicroRNAs in schizophrenia in the context of common genetic risk variants. JAMA Psychiatry, 73(4), 369–377. https://doi.org/10.1001/jamapsychiatry.2015.3018
Hoffman, G. E., & Brennand, K. J. (2018). Mapping regulatory variants in hiPSC models. Nature Genetics, 50(1), 1–2. https://doi.org/10.1038/s41588-017-0017-4
Roussos, P., Guennewig, B., Kaczorowski, D. C., Barry, G., & Brennand, K. J. (2016). Activity-dependent changes in gene expression in schizophrenia human-induced pluripotent stem cell neurons. JAMA Psychiatry, 73(11), 1180–1188. https://doi.org/10.1001/jamapsychiatry.2016.2575
Yoshimizu, T., Pan, J. Q., Mungenast, A. E., Madison, J. M., Su, S., Ketterman, J., et al. (2015). Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons. Molecular Psychiatry, 20(2), 162–169. https://doi.org/10.1038/mp.2014.143
Forrest, M. P., Zhang, H., Moy, W., McGowan, H., Leites, C., Dionisio, L. E., et al. (2017). Open chromatin profiling in hiPSC-derived neurons prioritizes functional noncoding psychiatric risk variants and highlights neurodevelopmental loci. Cell Stem Cell, 21(3), 305–318. e308. https://doi.org/10.1016/j.stem.2017.07.008
Powell, S. K., Gregory, J., Akbarian, S., & Brennand, K. J. (2017). Application of CRISPR/Cas9 to the study of brain development and neuropsychiatric disease. Molecular and Cellular Neurosciences, 82, 157–166. https://doi.org/10.1016/j.mcn.2017.05.007
Ho, S. M., Hartley, B. J., Flaherty, E., Rajarajan, P., Abdelaal, R., Obiorah, I., et al. (2017). Evaluating synthetic activation and repression of neuropsychiatric-related genes in hiPSC-derived NPCs, neurons, and astrocytes. Stem Cell Reports, 9(2), 615–628. https://doi.org/10.1016/j.stemcr.2017.06.012
Jiang, Y., Loh, Y. E., Rajarajan, P., Hirayama, T., Liao, W., Kassim, B. S., et al. (2017). The methyltransferase SETDB1 regulates a large neuron-specific topological chromatin domain. Nature Genetics, 49(8), 1239–1250. https://doi.org/10.1038/ng.3906
Rajarajan, P., Jiang, Y., Kassim, B. S., & Akbarian, S. (2018b). Chromosomal conformations and epigenomic regulation in schizophrenia. Progress in Molecular Biology and Translational Science, 157, 21–40. https://doi.org/10.1016/bs.pmbts.2017.11.022
Zarrei, M., MacDonald, J. R., Merico, D., & Scherer, S. W. (2015). A copy number variation map of the human genome. Nature Reviews Genetics, 16(3), 172–183. https://doi.org/10.1038/nrg3871
Ahn, K., Gotay, N., Andersen, T. M., Anvari, A. A., Gochman, P., Lee, Y., et al. (2014). High rate of disease-related copy number variations in childhood onset schizophrenia. Molecular Psychiatry, 19(5), 568–572. https://doi.org/10.1038/mp.2013.59
Flaherty E. K., Brennand K. J., (2017) Using hiPSCs to model neuropsychiatric copy number variations (CNVs) has potential to reveal underlying disease mechanisms. Brain Research 1655:283–293
Gothelf, D., Eliez, S., Thompson, T., Hinard, C., Penniman, L., Feinstein, C., et al. (2005). COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nature Neuroscience, 8(11), 1500–1502. https://doi.org/10.1038/nn1572
Gothelf, D., Feinstein, C., Thompson, T., Gu, E., Penniman, L., Van Stone, E., et al. (2007). Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. The American Journal of Psychiatry, 164(4), 663–669. https://doi.org/10.1176/ajp.2007.164.4.663
Murphy, K. C., Jones, L. A., & Owen, M. J. (1999). High rates of schizophrenia in adults with velo-cardio-facial syndrome. Archives of General Psychiatry, 56(10), 940–945.
Pedrosa, E., Sandler, V., Shah, A., Carroll, R., Chang, C., Rockowitz, S., et al. (2011). Development of patient-specific neurons in schizophrenia using induced pluripotent stem cells. Journal of Neurogenetics, 25(3), 88–103. https://doi.org/10.3109/01677063.2011.597908
Lin, M., Pedrosa, E., Hrabovsky, A., Chen, J., Puliafito, B. R., Gilbert, S. R., et al. (2016). Integrative transcriptome network analysis of iPSC-derived neurons from schizophrenia and schizoaffective disorder patients with 22q11.2 deletion. BMC Systems Biology, 10(1), 105. https://doi.org/10.1186/s12918-016-0366-0
Zhao, D., Lin, M., Chen, J., Pedrosa, E., Hrabovsky, A., Fourcade, H. M., et al. (2015). MicroRNA profiling of neurons generated using induced pluripotent stem cells derived from patients with schizophrenia and schizoaffective disorder, and 22q11.2 Del. PLoS One, 10(7), e0132387. https://doi.org/10.1371/journal.pone.0132387
Toyoshima, M., Akamatsu, W., Okada, Y., Ohnishi, T., Balan, S., Hisano, Y., et al. (2016). Analysis of induced pluripotent stem cells carrying 22q11.2 deletion. Translational Psychiatry, 6(11), e934. https://doi.org/10.1038/tp.2016.206
Warnica, W., Merico, D., Costain, G., Alfred, S. E., Wei, J., Marshall, C. R., et al. (2015). Copy number variable microRNAs in schizophrenia and their neurodevelopmental gene targets. Biological Psychiatry, 77(2), 158–166. https://doi.org/10.1016/j.biopsych.2014.05.011
Yoon, K. J., Nguyen, H. N., Ursini, G., Zhang, F., Kim, N. S., Wen, Z., et al. (2014). Modeling a genetic risk for schizophrenia in iPSCs and mice reveals neural stem cell deficits associated with adherens junctions and polarity. Cell Stem Cell, 15(1), 79–91. https://doi.org/10.1016/j.stem.2014.05.003
McCarthy S. E., Makarov V., Kirov G., Addington A. M., McClellan J., Yoon S., et al. (2009) Microduplications of 16p11.2 are associated with schizophrenia. Nature Genetics 41 (11):1223–1227
Deshpande, A., Yadav, S., Dao, D. Q., Wu, Z. Y., Hokanson, K. C., Cahill, M. K., et al. (2017). Cellular phenotypes in human iPSC-derived neurons from a genetic model of autism spectrum disorder. Cell Reports, 21(10), 2678–2687. https://doi.org/10.1016/j.celrep.2017.11.037
Rujescu, D., Ingason, A., Cichon, S., Pietilainen, O. P., Barnes, M. R., Toulopoulou, T., et al. (2009). Disruption of the neurexin 1 gene is associated with schizophrenia. Human Molecular Genetics, 18(5), 988–996. https://doi.org/10.1093/hmg/ddn351
Zeng, L., Zhang, P., Shi, L., Yamamoto, V., Lu, W., & Wang, K. (2013). Functional impacts of NRXN1 knockdown on neurodevelopment in stem cell models. PLoS One, 8(3), e59685. https://doi.org/10.1371/journal.pone.0059685
Pak, C., Danko, T., Zhang, Y., Aoto, J., Anderson, G., Maxeiner, S., et al. (2015). Human neuropsychiatric disease modeling using conditional deletion reveals synaptic transmission defects caused by heterozygous mutations in NRXN1. Cell Stem Cell, 17(3), 316–328. https://doi.org/10.1016/j.stem.2015.07.017
Flaherty E., Zhu S., Barretto N., Cheng E., Michael Deans P. J., Fernando M. B., et al. (2019) Neuronal impact of patient-specific aberrant NRXN1α splicing. Nature Genetics 51 (12):1679–1690
Jacobs, P., Brunton, M., Frackiewicz, A., Newton, M., Cook, P., & Robson, E. (1970). Studies on a family with three cytogenetic markers. Annals of Human Genetics, 33, 325–336.
St Clair, D., Blackwood, D., Muir, W., Carothers, A., Walker, M., Spowart, G., et al. (1990). Association within a family of a balanced autosomal translocation with major mental illness. Lancet, 336(8706), 13–16.
Millar, J. K., Wilson-Annan, J. C., Anderson, S., Christie, S., Taylor, M. S., Semple, C. A., et al. (2000). Disruption of two novel genes by a translocation co-segregating with schizophrenia. Human Molecular Genetics, 9(9), 1415–1423.
Sachs, N. A., Sawa, A., Holmes, S. E., Ross, C. A., DeLisi, L. E., & Margolis, R. L. (2005). A frameshift mutation in Disrupted in Schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder. Molecular Psychiatry, 10(8), 758–764. https://doi.org/10.1038/sj.mp.4001667
Green, E. K., Norton, N., Peirce, T., Grozeva, D., Kirov, G., Owen, M. J., et al. (2006). Evidence that a DISC1 frame-shift deletion associated with psychosis in a single family may not be a pathogenic mutation. Molecular Psychiatry, 11(9), 798–799. https://doi.org/10.1038/sj.mp.4001853
Chiang, C. H., Su, Y., Wen, Z., Yoritomo, N., Ross, C. A., Margolis, R. L., et al. (2011). Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. Molecular Psychiatry, 16(4), 358–360. https://doi.org/10.1038/mp.2011.13
Wen, Z., Nguyen, H. N., Guo, Z., Lalli, M. A., Wang, X., Su, Y., et al. (2014). Synaptic dysregulation in a human iPS cell model of mental disorders. Nature, 515(7527), 414–418. https://doi.org/10.1038/nature13716
Murai, K., Sun, G., Ye, P., Tian, E., Yang, S., Cui, Q., et al. (2016). The TLX-miR-219 cascade regulates neural stem cell proliferation in neurodevelopment and schizophrenia iPSC model. Nature Communications, 7, 10965. https://doi.org/10.1038/ncomms10965
Yalla, K., Elliott, C., Day, J. P., Findlay, J., Barratt, S., Hughes, Z. A., et al. (2018). FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system. Molecular Psychiatry, 23(5), 1278–1286. https://doi.org/10.1038/mp.2017.138
Chiu, F. L., Lin, J. T., Chuang, C. Y., Chien, T., Chen, C. M., Chen, K. H., et al. (2015). Elucidating the role of the A2A adenosine receptor in neurodegeneration using neurons derived from Huntington’s disease iPSCs. Human Molecular Genetics, 24(21), 6066–6079. https://doi.org/10.1093/hmg/ddv318
Chien, T., Weng, Y. T., Chang, S. Y., Lai, H. L., Chiu, F. L., Kuo, H. C., et al. (2018). GSK3beta negatively regulates TRAX, a scaffold protein implicated in mental disorders, for NHEJ-mediated DNA repair in neurons. Molecular Psychiatry. https://doi.org/10.1038/s41380-017-0007-z
Srikanth, P., Han, K., Callahan, D. G., Makovkina, E., Muratore, C. R., Lalli, M. A., et al. (2015). Genomic DISC1 disruption in hiPSCs alters Wnt signaling and neural cell fate. Cell Reports, 12(9), 1414–1429. https://doi.org/10.1016/j.celrep.2015.07.061
Bradshaw, N. J., & Porteous, D. J. (2012). DISC1-binding proteins in neural development, signalling and schizophrenia. Neuropharmacology, 62(3), 1230–1241. https://doi.org/10.1016/j.neuropharm.2010.12.027
Camargo, L. M., Collura, V., Rain, J. C., Mizuguchi, K., Hermjakob, H., Kerrien, S., et al. (2007). Disrupted in schizophrenia 1 interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Molecular Psychiatry, 12(1), 74–86. https://doi.org/10.1038/sj.mp.4001880
Camargo, L. M., Wang, Q., & Brandon, N. J. (2008). What can we learn from the disrupted in schizophrenia 1 interactome: lessons for target identification and disease biology? Novartis Foundation Symposium, 289, 208–216; discussion 216-221, 238-240.
Teng, S., Thomson, P. A., McCarthy, S., Kramer, M., Muller, S., & Lihm, J. (2018). Rare disruptive variants in the DISC1 Interactome and Regulome: association with cognitive ability and schizophrenia. Molecular Psychiatry, 23(5), 1270–1277. https://doi.org/10.1038/mp.2017.115
Nakata, K., Lipska, B. K., Hyde, T. M., Ye, T., Newburn, E. N., Morita, Y., et al. (2009). DISC1 splice variants are upregulated in schizophrenia and associated with risk polymorphisms. Proceedings of the National Academy of Sciences of the United States of America, 106(37), 15873–15878. https://doi.org/10.1073/pnas.0903413106
Wilkinson, B., Evgrafov, O. V., Zheng, D., Hartel, N., Knowles, J. A., Graham, N. A., et al. (2018). Endogenous cell type-specific disrupted in schizophrenia 1 interactomes reveal protein networks associated with neurodevelopmental disorders. Biological Psychiatry, 85, 305. https://doi.org/10.1016/j.biopsych.2018.05.009
Turner, T. N., Yi, Q., Krumm, N., Huddleston, J., Hoekzema, K., Stessman, H. A., et al. (2017). denovo-db: a compendium of human de novo variants. Nucleic Acids Research, 45(D1), D804–D811. https://doi.org/10.1093/nar/gkw865
Bakircioglu, M., Carvalho, O. P., Khurshid, M., Cox, J. J., Tuysuz, B., Barak, T., et al. (2011). The essential role of centrosomal NDE1 in human cerebral cortex neurogenesis. American Journal of Human Genetics, 88(5), 523–535. https://doi.org/10.1016/j.ajhg.2011.03.019
Ye, F., Kang, E., Yu, C., Qian, X., Jacob, F., Yu, C., et al. (2017). DISC1 regulates neurogenesis via modulating kinetochore attachment of Ndel1/Nde1 during mitosis. Neuron, 96(5), 1041–1054. e1045. https://doi.org/10.1016/j.neuron.2017.10.010
Mathieson, I., Munafo, M. R., & Flint, J. (2012). Meta-analysis indicates that common variants at the DISC1 locus are not associated with schizophrenia. Molecular Psychiatry, 17(6), 634–641. https://doi.org/10.1038/mp.2011.41
Richards, A. L., Leonenko, G., Walters, J. T., Kavanagh, D. H., Rees, E. G., Evans, A., et al. (2016). Exome arrays capture polygenic rare variant contributions to schizophrenia. Human Molecular Genetics, 25(5), 1001–1007. https://doi.org/10.1093/hmg/ddv620
Farrell, M. S., Werge, T., Sklar, P., Owen, M. J., Ophoff, R. A., O'Donovan, M. C., et al. (2015). Evaluating historical candidate genes for schizophrenia. Molecular Psychiatry, 20(5), 555–562. https://doi.org/10.1038/mp.2015.16
Sullivan, P. F. (2013). Questions about DISC1 as a genetic risk factor for schizophrenia. Molecular Psychiatry, 18(10), 1050–1052. https://doi.org/10.1038/mp.2012.182
Lee I. S., Carvalho C. M. B., Douvaras P., Ho S-M, Hartley B. J., Zuccherato L. W., et al. (2015) Characterization of molecular and cellular phenotypes associated with a heterozygous CNTNAP2 deletion using patient-derived hiPSC neural cells. npj Schizophrenia 1 (1)
Flaherty, E., Deranieh, R. M., Artimovich, E., Lee, I. S., Siegel, A. J., Levy, D. L., et al. (2017). Patient-derived hiPSC neurons with heterozygous CNTNAP2 deletions display altered neuronal gene expression and network activity. NPJ Schizophrenia, 3, 35. https://doi.org/10.1038/s41537-017-0033-5
de Vrij, F. M., Bouwkamp, C. G., Gunhanlar, N., Shpak, G., Lendemeijer, B., Baghdadi, M., et al. (2018). Candidate CSPG4 mutations and induced pluripotent stem cell modeling implicate oligodendrocyte progenitor cell dysfunction in familial schizophrenia. Molecular Psychiatry, 24, 757. https://doi.org/10.1038/s41380-017-0004-2
Guennewig, B., Bitar, M., Obiorah, I., Hanks, J., O'Brien, E. A., Kaczorowski, D. C., et al. (2018). THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Translational Psychiatry, 8(1), 89. https://doi.org/10.1038/s41398-018-0137-3
Obiorah, I. V., Muhammad, H., Stafford, K., Flaherty, E. K., & Brennand, K. J. (2017). THC treatment alters glutamate receptor gene expression in human stem cell-derived neurons. Molecular Neuropsychiatry, 3(2), 73–84. https://doi.org/10.1159/000477762
Khandaker, G. M., Zimbron, J., Lewis, G., & Jones, P. B. (2013). Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychological Medicine, 43(2), 239–257. https://doi.org/10.1017/S0033291712000736
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., et al. (2015). Schizophrenia. Nature Reviews Disease Primers, 1, 15067. https://doi.org/10.1038/nrdp.2015.67
Walsh, N. C., Kenney, L. L., Jangalwe, S., Aryee, K. E., Greiner, D. L., Brehm, M. A., et al. (2017). Humanized mouse models of clinical disease. Annual Review of Pathology, 12, 187–215. https://doi.org/10.1146/annurev-pathol-052016-100332
Allswede, D. M., Buka, S. L., Yolken, R. H., Torrey, E. F., & Cannon, T. D. (2016). Elevated maternal cytokine levels at birth and risk for psychosis in adult offspring. Schizophrenia Research, 172(1–3), 41–45. https://doi.org/10.1016/j.schres.2016.02.022
Lin, M., Zhao, D., Hrabovsky, A., Pedrosa, E., Zheng, D., & Lachman, H. M. (2014). Heat shock alters the expression of schizophrenia and autism candidate genes in an induced pluripotent stem cell model of the human telencephalon. PLoS One, 9(4), e94968. https://doi.org/10.1371/journal.pone.0094968
Hashimoto-Torii, K., Torii, M., Fujimoto, M., Nakai, A., El Fatimy, R., Mezger, V., et al. (2014). Roles of heat shock factor 1 in neuronal response to fetal environmental risks and its relevance to brain disorders. Neuron, 82(3), 560–572. https://doi.org/10.1016/j.neuron.2014.03.002
Ishii, S., Torii, M., Son, A. I., Rajendraprasad, M., Morozov, Y. M., Kawasawa, Y. I., et al. (2017). Variations in brain defects result from cellular mosaicism in the activation of heat shock signalling. Nature Communications, 8, 15157. https://doi.org/10.1038/ncomms15157
Vallersnes, O. M., Dines, A. M., Wood, D. M., Yates, C., Heyerdahl, F., Hovda, K. E., et al. (2016). Psychosis associated with acute recreational drug toxicity: a European case series. BMC Psychiatry, 16, 293. https://doi.org/10.1186/s12888-016-1002-7
Callaghan, R. C., Cunningham, J. K., Allebeck, P., Arenovich, T., Sajeev, G., Remington, G., et al. (2012). Methamphetamine use and schizophrenia: a population-based cohort study in California. The American Journal of Psychiatry, 169(4), 389–396. https://doi.org/10.1176/appi.ajp.2011.10070937
Nielsen, S. M., Toftdahl, N. G., Nordentoft, M., & Hjorthoj, C. (2017). Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study. Psychological Medicine, 47(9), 1668–1677. https://doi.org/10.1017/S0033291717000162
de Leon, J., & Diaz, F. J. (2005). A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Research, 76(2–3), 135–157. https://doi.org/10.1016/j.schres.2005.02.010
Pasman, J. A., Verweij, K. J. H., Gerring, Z., Stringer, S., Sanchez-Roige, S., Treur, J. L., et al. (2018). GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nature Neuroscience, 21(9), 1161–1170. https://doi.org/10.1038/s41593-018-0206-1
Chatterton, Z., Hartley, B. J., Seok, M. H., Mendelev, N., Chen, S., Milekic, M., et al. (2017). In utero exposure to maternal smoking is associated with DNA methylation alterations and reduced neuronal content in the developing fetal brain. Epigenetics & Chromatin, 10, 4. https://doi.org/10.1186/s13072-017-0111-y
Oedegaard, K. J., Alda, M., Anand, A., Andreassen, O. A., Balaraman, Y., Berrettini, W. H., et al. (2016). The pharmacogenomics of bipolar disorder study (PGBD): identification of genes for lithium response in a prospective sample. BMC Psychiatry, 16, 129. https://doi.org/10.1186/s12888-016-0732-x
Ruderfer, D. M., Charney, A. W., Readhead, B., Kidd, B. A., Kahler, A. K., Kenny, P. J., et al. (2016). Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. Lancet Psychiatry, 3(4), 350–357. https://doi.org/10.1016/S2215-0366(15)00553-2
Li, J., Yoshikawa, A., Brennan, M. D., Ramsey, T. L., & Meltzer, H. Y. (2018). Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes. Schizophrenia Research, 192, 194–204. https://doi.org/10.1016/j.schres.2017.04.009
Kim, Y., Giusti-Rodriguez, P., Crowley, J. J., Bryois, J., Nonneman, R. J., Ryan, A. K., et al. (2018). Comparative genomic evidence for the involvement of schizophrenia risk genes in antipsychotic effects. Molecular Psychiatry, 23(3), 708–712. https://doi.org/10.1038/mp.2017.111
Readhead, B., Hartley, B. J., Eastwood, B. J., Collier, D. A., Evans, D., & Farias, R. (2018). Expression-based drug screening of neural progenitor cells from individuals with schizophrenia. Nature Communications, 9(1), 4412. https://doi.org/10.1038/s41467-018-06515-4
Xu, M., Lee, E. M., Wen, Z., Cheng, Y., Huang, W. K., Qian, X., et al. (2016). Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nature Medicine, 22(10), 1101–1107. https://doi.org/10.1038/nm.4184
Zhou, T., Tan, L., Cederquist, G. Y., Fan, Y., Hartley, B. J., Mukherjee, S., et al. (2017). High-content screening in hPSC-neural progenitors identifies drug candidates that inhibit Zika virus infection in fetal-like organoids and adult brain. Cell Stem Cell, 21(2), 274–283. e275. https://doi.org/10.1016/j.stem.2017.06.017
Watanabe, M., Buth, J. E., Vishlaghi, N., de la Torre-Ubieta, L., Taxidis, J., Khakh, B. S., et al. (2017). Self-organized cerebral organoids with human-specific features predict effective drugs to combat Zika virus infection. Cell Reports, 21(2), 517–532. https://doi.org/10.1016/j.celrep.2017.09.047
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Powell, S.K., O’Shea, C.P., Shannon, S.R., Akbarian, S., Brennand, K.J. (2020). Investigation of Schizophrenia with Human Induced Pluripotent Stem Cells. In: DiCicco-Bloom, E., Millonig, J. (eds) Neurodevelopmental Disorders . Advances in Neurobiology, vol 25. Springer, Cham. https://doi.org/10.1007/978-3-030-45493-7_6
Download citation
DOI: https://doi.org/10.1007/978-3-030-45493-7_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-45492-0
Online ISBN: 978-3-030-45493-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)